AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Goldfinch Bio to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 7, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 7, 2020--

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the 38 th Annual J.P. Morgan Healthcare Conference. During the presentation, Dr. Johnson will provide a review of 2019 accomplishments and introduce the Company’s 2020 strategic outlook. The presentation will take place on Tuesday, January 14, 2020 at 12:00 p.m. PT at the Westin St. Francis in San Francisco.

About Goldfinch Bio

Goldfinch Bio, Inc. is a clinical stage biotechnology company that leverages a genomics-based, precision medicine approach to discovering and developing kidney disease treatments. Its Kidney Genome Atlas TM is a proprietary biology platform that drives candidate discovery, patient selection and biomarker development. The Company’s lead candidate, GFB-887, is a transient receptor potential canonical 5 (TRPC5) ion channel inhibitor being evaluated in a Phase 1 clinical trial for the treatment of kidney diseases. Goldfinch Bio is also developing GFB-024, a peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody, for the treatment of rare and metabolic kidney diseases and expects to submit an IND in the second half of 2020. Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc. For more information about Goldfinch Bio, visit www.goldfinchbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005345/en/

CONTACT: Goldfinch Bio:

Investors:

Argot Partners

Kimberly Minarovich / Joseph Rayne

212-600-1902

kimberly@argotpartners.comorjoseph@argotpartners.comMedia:

David Rosen, 212-600-1902

david.rosen@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE

SOURCE: Goldfinch Bio, Inc.

Copyright Business Wire 2020.

PUB: 01/07/2020 07:00 AM/DISC: 01/07/2020 07:01 AM

http://www.businesswire.com/news/home/20200107005345/en